Patients
hypertension, Cancer
HYPERTENSION, CANCER
This study was approved by the Health Research Ethics Board of Alberta Cancer Committee (HREBA‐CC 14–0074). Data and samples used were derived from an international, multicenter, double‐blind, randomized controlled phase III study examining the benefits of adding brivanib to third‐line cetuximab (NCIC‐CTG CO.20) in patients with KRAS wild‐type metastatic CRC who progressed on combinations of a oxaliplatin, irinotecan and fluoropyrimidine.Brivanib‐associated hypertension was defined as new onset hypertension after starting the drug, or an exacerbation of hypertension following treatment initiation. In the experimental arm (cetuximab plus brivanib), cases with treatment‐related hypertension (A Consort diagram depicting patient and data flow used in the analyses. Blue boxes indicate comparator groups/samples. (A) Consort diagram representing comparison of clinical characteristics and outcomes associated with brivanib‐induced hypertension. (B) Sample selection for metabolomic biomarker discovery and validation.